During a live event, Michael R. Bishop, MD, discussed a case of steroid-refractory GVHD and the efficacy and safety outcomes ...

“With the approval of Niktimvo, patients with chronic GVHD whose disease has progressed after prior therapies, now have a new treatment option with a novel mechanism of action to help address the ...

Please provide your email address to receive an email when new articles are posted on . Impairment of social life was listed as an ongoing quality-of-life impact for every patient. Psychological and ...

Incyte and Syndax will seek approval to launch two smaller vial sizes following the FDA's approval of Niktimvo (as a 50mg vial). Following FDA approval of the new vial sizes, the companies anticipate ...

The FDA approved axatilimab-csfr for certain patients with chronic graft-versus-host disease. The indication applies to use of the therapy by adults and children who failed at least two prior lines of ...

Bone marrow, or hematopoietic stem cell, transplantation (HCT) is frequently used to treat patients with leukemia by replacing the diseased bone marrow with healthy bone marrow from a donor. Yet, a ...

Findings from the phase 2 AGAVE-201 study showed an ORR of 75%, with all responders having a partial response. The Food and Drug Administration (FDA) has approved Niktimvo (axatilimab-csfr) for the ...

Chronic graft-versus-host disease (GVHD) refractory to standard immunosuppressive therapy remains a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT).

A 37-year-old female who had undergone a matched unrelated allogeneic BMT 2 years prior to admission presented with a several month history of progressive weakness of the muscles of both shoulders, ...

Graft-versus-host disease (GVHD) symptoms can range from mild to severe, and all of them can have an impact on your quality of life in different ways. The symptoms of acute GVHD, which often occurs ...

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease. The Food and Drug Administration (FDA) approved Niktimvo (axatilimab-csfr) for the treatment of ...